Oliver Wyman April 24, 2024
We’ve identified four strategic areas that pharmaceutical companies must examine to sustain attractive rare disease pricing and market access.
Treating rare diseases has always been a conundrum for the healthcare industry. While patients and families eagerly await new therapies, limited market sizes and substantial investment in research and development lead to high treatment costs.
With the annual cost of treating a rare disease patient pharmacologically in the US reaching $32,000 on average, and over $100,000 in one third of the cases, the industry needs a more sustainable model — one that addresses both affordability and access. We are starting to see a migration in that direction as payers increasingly scrutinize these price levels. Much of this is being driven by...
Today's Sponsors
Today's Sponsor